Texas high-speed bullet train has some fresh financial fuel. Photo of the N700 courtesy of © JR Central

Amtrak and its partners will receive more than $2.1 billion in a federal program to improve existing routes and expand Amtrak service across the U.S.

That includes $500,000 from the Federal Railroad Administration awarded to the long-in-the-works high-speed rail project between Houston and Dallas, as well as another $500,000 awarded to the I-20 Corridor Long-Distance Passenger Rail Project.

The funding is via the newly-passed Infrastructure Investment & Jobs Act and includes multiple grants that will go to Amtrak and partners. This includes:

  • $108.5 million to Amtrak for station and service upgrades;
  • $2 billion to Amtrak partners in North Carolina, Virginia, Pennsylvania, and Maine for infrastructure upgrades
  • $34.5 million to 39 states and localities for planning and development of 69 new and improved intercity passenger rail corridors

These grants were awarded through the Federal Railroad Administration’s Federal-State Partnership for Intercity Passenger Rail Program for projects located across the National Network, as well as the Corridor Identification and Development Program (Corridor ID).

FRA Administrator Amit Bose says in a statement that these will be "transformative rail projects" that will provide climate-friendly alternatives to congested roads and airports.

“Today’s investments in passenger rail nationwide, made possible by the President’s Bipartisan Infrastructure Law, are another step forward as we expand and modernize our country’s rail network, providing more Americans the world-class passenger rail they need and deserve," Bose says.

Amtrak was awarded funding on a variety of projects, including four Corridor programs, designed to create a pipeline of intercity passenger rail projects.

Those include:

  • Texas High-Speed Rail Corridor. This proposed corridor would connect Houston and Dallas, Texas, with a new, dedicated and grade separated high-speed passenger rail service. This would provide new service on a new alignment, with station stops in Dallas, Brazos Valley and Houston.
  • Long Island Northeast Regional Extension. This proposed corridor would extend three existing daily Northeast Regional round trips between Washington, DC and New York City east to Ronkonkoma, NY, with stops at Jamaica (Queens, NY) and Hicksville, NY. This would entail track, station and infrastructure upgrades to accommodate these trains and better integrate Amtrak service with Long Island Rail Road commuter service.
  • Daily Cardinal Service. This proposed corridor would increase Cardinal service to operate daily, versus three days per week currently. This route operates between New York City and Chicago via Philadelphia, Baltimore, Washington, DC, Virginia, West Virginia, Kentucky, Ohio and Indiana.
  • Daily Sunset Limited Service. This proposed corridor would increase Sunset Limited service to operate daily, versus three days per week currently. This route operates between Los Angeles and New Orleans via Houston, San Antonio and El Paso, Texas; Tucson, Ariz.; and other communities.

The release does not say exactly how the $500,000 will be used. According to TxDOT, the current estimate for construction of track between Houston and Dallas is approximately $16 billion.

------

This article originally ran on CultureMap.

Texas Central Partners hopes to partner with Amtrak on high-speed trains in Texas. Rendering courtesy of Texas Central

Houston-Dallas high-speed bullet train gets back on the rails thanks to potential Amtrak partnership

speeding back

In the latest chapter in the saga of the high-speed bullet train between Houston and Dallas, Amtrak is now involved.

According to a press release, Texas Central Partners and Amtrak are exploring a partnership to work together on the proposed Dallas-Houston high-speed rail project that's been under consideration for more than a decade.

Amtrak has cooperated with Texas Central on various initiatives since 2016 and the two entities are now evaluating a potential partnership to determine the line's viability.

“If we are going to add more high-speed rail to this country, the Dallas to Houston Corridor is a compelling proposition and offers great potential,” says Amtrak senior VP of High-Speed Rail Development Programs Andy Byford. “We believe many of the country's biggest and fastest-growing metropolitan areas, like Houston and Dallas, deserve more high quality high-speed, intercity rail service, and we are proud to bring our experience to evaluate this potential project and explore opportunities with Texas Central so the state can meet its full transportation needs.”

The route being proposed would span approximately 240 miles, going at 250 mph, resulting in a trip that would take less than 90 minutes between the two cities.

Texas Central has been working towards getting a train rolling since 2013, including lining up a potential builder in 2021. But the project has had pushback from Texas politicians and landowners along the route; a lawsuit against the project was filed by six rural counties in 2021, and the Texas Legislature passed a law prohibiting the state from spending any funds on the project.

Facing a seeming dead end, Texas Central CEO Carlos Aguilar and its board members resigned in June 2022; Michael Bui, a consultant, has been serving as CEO since then.

Texas Central and Amtrak have submitted applications to several federal programs in connection with further study and design work, including the Consolidated Rail Infrastructure Safety and Improvements (CRISI) grant program, the Corridor Identification and Development program, and the Federal-State Partnership for Intercity Passenger Rail (FSP-National) grant program.

Amtrak previously entered into an agreement with Texas Central to provide through-ticketing using the Amtrak reservation system and other support services for the planned high-speed rail line.

"This high-speed train, using advanced, proven Shinkansen technology, has the opportunity to revolutionize rail travel in the southern U.S., and we believe Amtrak could be the perfect partner to help us achieve that,” says Bui in a statement.

Despite its detractors, the project is forecast to provide social, environmental, employment and economic benefits including reducing greenhouse gas emissions by more than 100,000 tons per year, saving 65 million gallons of fuel and removing 12,500 cars per day from I-45.

The release from Amtrak has statements from both Dallas Mayor Eric L. Johnson and Houston Mayor Sylvester Turner, who calls the collaboration between Texas Central and Amtrak "an important milestone for the City of Houston and this project."

Byford joined Amtrak in April 2023 to begin developing a team focused on high-speed opportunities throughout the U.S. In his newly created role, he will develop and lead the execution of Amtrak’s long-term strategy for high-speed rail throughout the country, including the extension of the Crescent from Mississippi through Louisiana and Texas; Kansas DOT’s Heartland Flyer Extension Corridor Identification and Development (Corridor ID) connecting Wichita to Oklahoma and Texas, and TxDOT’s applications for the Texas Triangle (Houston — Dallas – Fort Worth – San Antonio) routes.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

Houston business mogul Tilman Fertitta acquires Caesars in $17.6B deal

Money Moves

Houston billionaire Tilman Fertitta may currently be serving as America’s ambassador to Italy, but his company is as busy as ever. Fresh off its move to revive the Houston Comets WNBA franchise, his company, Fertitta Entertainment, has announced a $17.6 billion deal to acquire Caesars Entertainment, Inc.

Speculation about the deal has been circulating since at least March, according to various media reports. The deal combines Fertitta’s well-known Golden Nugget casino brand with all of the properties in the Caesars’ portfolio, including Las Vegas hotels Caesars Palace, Harrah's, Paris Las Vegas, Planet Hollywood, Horseshoe, The LINQ Hotel, Flamingo, and The Cromwell.

Overall, the combined company will include 60 domestic casino resorts and gaming facilities; online gaming including sports betting, iCasino, and Caesar’s online poker platform; retail sports betting at over 200 third-party locations through the William Hill brand; and over 550 Fertitta Entertainment outlets, including more than 450 Landry's full-service restaurants across America. The companies will combine their loyalty programs, Caesars Rewards, Golden Nugget's 24 Karat Select Club, and Landry's Select Club.

The terms will see Caesars’ shareholders receive $31 per share. Fertitta Entertainment will also acquire approximately $11.9 billion of Caesars' outstanding debt.

The transaction will be financed through a combination of equity contributed by Fertitta Entertainment, assumed Caesars' debt, and new committed debt financing arranged by a group consisting of 10 banks. It is subject to approval by Caesars’ shareholders and government regulators.

Fertitta Entertainment is the Houston-based company behind a diverse array of hospitality businesses, including The Golden Nugget, The Post Oak Hotel, River Oaks District, the Kemah Boardwalk, and Houston’s Downtown Aquarium.

It also operates a number of prominent restaurant brands, including Mastro's Restaurants, Del Frisco's Double Eagle Steakhouse, Morton's The Steakhouse, The Palm, McCormick & Schmick's, Landry's Seafood House, The Oceanaire Seafood Room, and Saltgrass Steak House.

---

This article first appeared on CultureMap.com.

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.